Natalie Holles

President and Chief Executive Officer,
Audentes Therapeutics

Natalie has served as President and Chief Executive Officer of Audentes, an Astellas company, since January 2020. She has more than 20 years of executive leadership, business development, corporate strategy, and commercial experience gained in a range of therapeutic areas, with a particular focus on orphan diseases. She joined the company as Senior Vice President and Chief Operating Officer in August 2015 and was promoted to President and Chief Operating Officer in May 2018. Prior to joining Audentes, Natalie served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. (acquired by Horizon Pharma in 2015). Before that, she provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies. Earlier in her career, Natalie served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc.

Natalie holds an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute predoctoral fellow, and an A.B. in human biology from Stanford University.